Tenofovir disoproxil fumarate (TDF) is an antiretroviral medication commonly used in the treatment of HIV and hepatitis B. One of the potential side effects of TDF is renal toxicity, which can lead to kidney damage and impaired renal function. Therefore, it is important to monitor renal function in patients taking TDF to ensure that the drug is being safely metabolized by the kidneys.

The acceptable level for TDF use based on renal function is an estimated glomerular filtration rate (eGFR) greater than 50 mL/min/1.73 m². This level ensures that the kidneys are functioning well enough to metabolize the drug without causing further renal impairment. An eGFR below 50 mL/min/1.73 m² may indicate decreased kidney function and an increased risk of TDF-related renal toxicity.

Therefore, patients with an eGFR greater than 50 mL/min/1.73 m² are considered to have acceptable renal function for TDF use. It is important for healthcare providers to regularly monitor renal function in patients taking TDF to ensure that the drug is being safely metabolized and to prevent any potential kidney damage.

HIV, or human immunodeficiency virus, primarily targets and damages the immune system by attacking CD4 cells, which are crucial for fighting off infections. However, HIV can also directly damage other organ systems in the body.

The brain can be affected by HIV through various neurological complications, such as HIV-associated neurocognitive disorders (HAND) which can lead to cognitive impairment and dementia. The kidneys can also be damaged by HIV, leading to conditions like HIV-associated nephropathy (HIVAN) which can result in kidney failure.

Additionally, HIV can directly damage the heart, leading to cardiomyopathy which is a condition where the heart muscle becomes weakened and cannot pump blood effectively. Lastly, HIV can also affect the gonads, leading to issues with fertility and hormone production.

Therefore, the correct answer is: Brain, kidneys, heart, and gonads.

A high vaginal swab is not necessary for diagnosing vaginal candidiasis if the symptoms strongly suggest its presence. Symptoms such as genital itching and white discharge are indicative of Candida albicans infection. The discharge appears like cottage cheese and causes inflammation and itching, but the vaginal pH remains normal (around 4.0-4.5 in women of reproductive age). Since vaginal candidiasis is a common condition, a confident clinical suspicion based on the examination can be enough to diagnose and initiate treatment.

The other options for diagnosis are incorrect. Gardnerella vaginalis is a normal part of the vaginal flora, but it’s overgrowth can lead to bacterial vaginosis. Unlike vaginal candidiasis, bacterial vaginosis presents with thinner white discharge and a fishy odor that intensifies with the addition of potassium hydroxide. Additionally, the vaginal pH would be elevated (> 4.5).

Vaginal candidiasis, also known as thrush, is a common condition that many women can diagnose and treat themselves. Candida albicans is responsible for about 80% of cases, while other candida species cause the remaining 20%. Although most women have no predisposing factors, certain factors such as diabetes mellitus, antibiotics, steroids, pregnancy, and HIV can increase the likelihood of developing vaginal candidiasis. Symptoms include non-offensive discharge resembling cottage cheese, vulvitis, itching, vulvar erythema, fissuring, and satellite lesions. A high vaginal swab is not routinely indicated if the clinical features are consistent with candidiasis. Treatment options include local or oral therapy, with oral fluconazole 150 mg as a single dose being the first-line treatment according to NICE Clinical Knowledge Summaries. If there are vulval symptoms, a topical imidazole may be added to an oral or intravaginal antifungal. Pregnant women should only use local treatments. Recurrent vaginal candidiasis is defined as four or more episodes per year by BASHH. Compliance with previous treatment should be checked, and a high vaginal swab for microscopy and culture should be performed to confirm the diagnosis. A blood glucose test may be necessary to exclude diabetes, and differential diagnoses such as lichen sclerosus should be ruled out. An induction-maintenance regime involving oral fluconazole may be considered. Induction involves taking oral fluconazole every three days for three doses, while maintenance involves taking oral fluconazole weekly for six months.

Live virus vaccines contain a weakened or attenuated form of the virus, which can still replicate in the body but typically does not cause disease. Examples of live virus vaccines include Vaccinia (smallpox), Measles, Mumps, Rubella (MMR combined vaccine), Varicella (chickenpox), Influenza (nasal spray), Rotavirus, Zoster (shingles), and Yellow fever.

On the other hand, inactivated vaccines contain killed or inactivated forms of the virus or bacteria, which cannot replicate in the body. Examples of inactivated vaccines include Polio (IPV), Hepatitis A, and Rabies.

Based on this information, the vaccines that do not contain live organisms are Polio (Salk), Typhoid (TY 21a), and Polio (Salk) (listed twice in the question). These vaccines are inactivated vaccines, meaning they do not contain live organisms.

Pregnant women with a CD4 count ≤ 350 cells/μL are considered to be at higher risk for developing active tuberculosis (TB) due to their compromised immune system. Therefore, it is recommended that these women receive TB preventive therapy (TPT) to reduce their risk of developing TB during pregnancy.

The recommended duration of TPT for pregnant women with a CD4 count ≤ 350 cells/μL is 12 months. This duration is based on clinical studies and guidelines that have shown that a 12-month course of TPT is effective in reducing the risk of developing active TB in this population.

It is important for pregnant women with a CD4 count ≤ 350 cells/μL to adhere to the full 12-month course of TPT to ensure maximum protection against TB. Additionally, healthcare providers should closely monitor these women throughout their pregnancy to ensure that they are responding well to the TPT and to address any potential side effects or complications that may arise.

The class of antidepressants that was developed through research on the treatment of tuberculosis is the MAOIs (Monoamine Oxidase Inhibitors). The first two MAOIs, isoniazid and iproniazid, were originally used to treat tuberculosis but were found to have mood-elevating effects in some patients. This led to their repurposing for the treatment of depression in 1957. However, due to concerns about toxicity, these specific MAOIs were withdrawn in 1961. Subsequently, other MAOIs were developed for the treatment of depression.

Amphetamines are not classified as antidepressants, as they are stimulants rather than mood stabilizers. Tetracyclics are closely related to tricyclic antidepressants, which were developed from research on anaesthetic agents. Overall, the history and classification of antidepressants are complex and varied, with different drugs being developed for different purposes and with different mechanisms of action.

For many of the approved antiretroviral agents, the FDA has stipulated specific age restrictions based on limited data in pediatric populations. Integrase strand transfer inhibitors (INSTIs) have increasingly been used for antiretroviral therapy, in combination with nucleoside reverse transcriptase inhibitors (NRTIs), due to excellent virologic activity and very few side effects. For this 10-year-old boy who weighs 32 kg, there are two preferred antiretroviral options, and both are INSTI-based regimens: bictegravir-tenofovir alafenamide-emtricitabine or dolutegravir plus 2 nucleoside reverse transcriptase inhibitors (NRTIs). The following summarizes the FDA approval status for the use of INSTIs in pediatric populations:

Bictegravir: This INSTI is only available in the fixed-dose combination bictegravir-tenofovir alafenamide-emtricitabine and this medication is FDA-approved for use in children who weigh at least 14 kg. Bictegravir-tenofovir alafenamide-emtricitabine is a preferred regimen in pediatric patients who are at least 2 years old and weigh at least 14 kg.
Cabotegravir: Long-acting injectable cabotegravir and rilpivirine is FDA-approved only for adults.
Dolutegravir: The FDA has approved the use of dolutegravir in children who are at least 4 weeks of age and weigh at least 3 kg. Dolutegravir plus two NRTIs is a preferred regimen in children who are at least 4 weeks of age and weigh at least 3 kg. The fixed dose combination dolutegravir-abacavir-lamivudine is FDA-approved for use in children who weigh at least 10 kg. The fixed-dose 2-drug oral regimens (dolutegravir-rilpivirine and dolutegravir-lamivudine) are recommended as single-tablet antiretroviral therapy regimens only for adults.
Elvitegravir: The fixed-dose single tablet medication elvitegravir-cobicistat-tenofovir alafenamide-emtricitabine is FDA-approved for use in children who weigh at least 25 kg. The fixed-dose single-tablet medication elvitegravir-cobicistat-tenofovir DF-emtricitabine is FDA-approved for use in children who weigh at least 35 kg. Elvitegravir-based regimens are not recommended as preferred antiretroviral regimens.
Raltegravir: The FDA has approved raltegravir for use in combination with other antiretroviral medication in children who weigh at least 2 kg. Raltegravir is available as an oral suspension, chewable tablets, and regular tablets. Raltegravir plus two NRTIs is a preferred regimen in children younger than 4 weeks of age who weigh at least 2 kg. The high-dose raltegravir (600 mg tablets) is given as 1200 mg once-daily, and this dosing is approved for use only in children who weigh at least 40 kg. Raltegravir is not available in any fixed-dose combinations.

Endotoxins are composed of Lipid A in lipopolysaccharide in the cell wall of Gram-negative bacteria. They are produced by Gram-negative bacteria, not Gram-positive bacteria. Endotoxins are composed of secreted polypeptides, not Lipid A in lipopolysaccharide. Endotoxins are heat labile, meaning they can be destroyed by heat. Endotoxins have four specialized secretion pathways. Lipopolysaccharides (LPS) are also known as endotoxins and are large molecules consisting of Lipid A and a polysaccharide composed of O-antigen, outer core, and inner core joined by a covalent bond.

Pneumocystis Pneumonia is a common opportunistic infection in individuals with HIV, particularly those with low CD4 counts. The symptoms of Pneumocystis Pneumonia include a dry cough, shortness of breath, fatigue, and fever. The fact that the patient has a low CD4 count of 25 cells/ul indicates severe immunosuppression, putting her at high risk for opportunistic infections like Pneumocystis Pneumonia. Additionally, the 3-week history of symptoms is consistent with the typical progression of Pneumocystis Pneumonia in HIV-positive individuals.

It is important for this patient to be promptly diagnosed and treated for Pneumocystis Pneumonia, as it can be a life-threatening infection in individuals with compromised immune systems. Treatment typically involves antibiotics such as trimethoprim-sulfamethoxazole (TMP-SMX) and corticosteroids. Additionally, initiation of antiretroviral therapy (ART) is crucial to improve the patient’s immune function and prevent future opportunistic infections.

Initiating antiretroviral therapy (ART) for newly diagnosed or known HIV-positive women not on ART the following day after excluding contra-indications is important for preventing mother-to-child transmission of HIV. By starting ART promptly, the viral load in the mother’s body can be suppressed, reducing the risk of transmission to the baby during labor and delivery. This timing allows for the maximum benefit of ART to be achieved in terms of reducing the risk of transmission.

Delaying the initiation of ART until after the first postnatal visit or only if the mother requests it may increase the risk of transmission to the baby. Therefore, it is recommended to start ART as soon as possible after diagnosis, once any contraindications have been ruled out. This approach is in line with current guidelines for the prevention of mother-to-child transmission of HIV and can significantly improve the health outcomes for both the mother and the baby.

In this case, the most appropriate investigation to make a diagnosis of active tuberculosis is sputum for acid-fast bacilli smear. This test involves collecting three-morning sputum samples and testing them for the presence of acid-fast bacilli using gram staining. This test is quick, provides fast results, and allows for prompt initiation of treatment if tuberculosis is confirmed.

Blood culture, on the other hand, would be less sensitive than sputum testing for diagnosing active tuberculosis. A chest X-ray would not be able to differentiate between active tuberculosis and old infection. The Mantoux test may be positive in cases of previous infection or vaccination against tuberculosis, but it does not confirm active disease. A CT chest would also not be able to differentiate between active infection and old tuberculosis findings.

Therefore, in this scenario, sputum for acid-fast bacilli smear is the most appropriate investigation to diagnose active tuberculosis.

The PMTCT program focuses on preventing HIV, syphilis, and TB transmissions from mothers to their infants. The pillars outlined in the program include primary prevention of HIV and TB, preventing unintended pregnancies among women living with HIV, preventing disease transmission from a woman diagnosed with syphilis to her infant, and providing appropriate treatment, care, and support to women living with HIV and their families.

The statement Providing appropriate treatment, care, and support to women living with TB, their children, partners, and families is not a pillar outlined in the PMTCT program. While it is important to provide appropriate treatment, care, and support to individuals living with TB, this specific aspect is not directly related to preventing transmissions from mothers to their infants. The focus of the PMTCT program is on preventing transmissions of HIV, syphilis, and TB specifically from mothers to their infants.

Persistent low-grade viremia on an NNRTI-based regimen can be concerning as it may indicate the development of drug resistance or suboptimal viral suppression. In such cases, it is important to consider switching to a more potent regimen to achieve better viral control and prevent further resistance.

Immediate regimen change to a PI-based regimen may be too aggressive and not necessary at this stage, as a single drug switch to TLD can often be effective in improving viral suppression. Referring to a third-line committee may be premature, as there are still options to explore before moving to third-line regimens.

Increasing the dosage of the current medication may not be effective in addressing persistent low-grade viremia, as the issue may be related to drug resistance or suboptimal drug potency. Therefore, considering a single drug switch to TLD is a reasonable approach to enhance viral suppression and improve treatment outcomes in this scenario.

When a woman living with HIV desires to conceive, it is important to take precautions to minimize the risk of transmission to the partner and the baby. The recommended action is to optimize HIV treatment in both partners, use condoms, and maintain an undetectable viral load.

Optimizing HIV treatment involves ensuring that both partners are on effective antiretroviral therapy to suppress the viral load to undetectable levels. This not only improves the health of the individuals but also significantly reduces the risk of transmission during conception. Using condoms further reduces the risk of transmission, as it provides an additional barrier against the virus.

Maintaining an undetectable viral load is crucial during conception, pregnancy, and breastfeeding to minimize the risk of transmission to the baby. It is important to continue regular medical monitoring and follow the guidance of healthcare providers throughout the process.

It is not recommended to advise against conception outright, as there are safe ways for individuals living with HIV to have children. By following these recommendations, individuals can have a healthy pregnancy and reduce the risk of transmitting the virus to their partner or baby.

For clients on ART with a viral load (VL) ≥ 1000 c/mL and adherence over 80%, the guidelines recommend focusing on improved adherence before considering any changes to the regimen. The rationale is that resistance to Dolutegravir (DTG), a common component in ART regimens, is very uncommon, so addressing adherence issues is crucial for achieving viral suppression.

Pregnant women who are already on antiretroviral therapy (ART) should continue their current regimen until their first viral load result is available. This is because it is important to ensure that the current regimen is effectively suppressing the virus before making any changes.

If the viral load result comes back as less than 50 copies/ml, then the preferred antiretroviral regimen for pregnant women is Tenofovir (TDF), Lamivudine (3TC), and Dolutegravir (DTG). This combination is recommended by the World Health Organization (WHO) as it is highly effective in suppressing the virus and has a good safety profile for both the mother and the baby.

This question is testing the candidate’s knowledge of the side effects of different antiretroviral agents used in the treatment of HIV. In this case, the patient developed poor sleep, nightmares, low mood, and suicidal ideation shortly after starting HAART, indicating a possible psychiatric side effect of one of the medications.

The correct answer is Efavirenz, which is a non-nucleoside reverse transcriptase inhibitor known to cause neuropsychiatric side effects, such as insomnia, vivid dreams, depression, and suicidal ideation. It is important for healthcare providers to be aware of these potential side effects and monitor patients closely, especially those without a history of mental health issues.

The other options provided in the question (Emtricitabine, Lamivudine, Rilpivirine, and Tenofovir) are also commonly used antiretroviral agents but are not typically associated with the psychiatric side effects described in the case. Emtricitabine and Lamivudine are nucleoside reverse transcriptase inhibitors, Rilpivirine is a non-nucleoside reverse transcriptase inhibitor, and Tenofovir is a nucleotide reverse transcriptase inhibitor. Each of these medications has its own set of potential side effects, but in this case, the symptoms described are most likely due to Efavirenz.

The most probable diagnosis for the 8-week-old baby with bilateral cataracts, thrombocytopenia, a patent ductus arteriosus, and hepatosplenomegaly is congenital rubella syndrome. This is because the clinical presentation matches the classic triad of symptoms associated with congenital rubella syndrome, which includes sensorineural hearing loss, ocular abnormalities such as cataracts, and congenital heart disease like a patent ductus arteriosus. Other common findings in congenital rubella syndrome include CNS abnormalities, hepatosplenomegaly, and jaundice. Therefore, the most likely cause of the baby’s symptoms is rubella infection during pregnancy.

This question presents a case of an 8-year-old boy with easy bruising following falls, leukocytosis, thrombocytopenia, high ESR, and a positive Paul-Bunnell test. The most probable diagnosis in this case is glandular fever, also known as infectious mononucleosis, caused by the Epstein-Barr virus (EBV).

Glandular fever is characterized by symptoms such as fatigue, fever, sore throat, and swollen lymph nodes. Leukocytosis is a common finding in infectious mononucleosis, and thrombocytopenia can also occur. The elevated ESR and positive Paul-Bunnell test further support the diagnosis of glandular fever in this case.

Idiopathic thrombocytopenic purpura (ITP) is a condition characterized by low platelet counts, but in this case, the combination of symptoms and test results point more towards glandular fever. Trauma and non-accidental injury (NAI) are less likely causes in this scenario, as the symptoms are more consistent with an underlying infectious process. Septicaemia is also less likely given the specific findings in this case.

In conclusion, the most probable diagnosis for this 8-year-old boy with easy bruising, leukocytosis, thrombocytopenia, high ESR, and a positive Paul-Bunnell test is glandular fever (infectious mononucleosis) caused by the Epstein-Barr virus.

The question is asking which of the listed options is NOT considered an antenatal risk factor for referral to a community health worker (CHW).

Teenage pregnancy, low birth weight baby, any maternal problem during or post-delivery, and substance use (tobacco, drugs, alcohol) are all commonly recognized antenatal risk factors that may warrant referral to a CHW for additional support and care.

Having a previous history of depression or anxiety is not specifically mentioned as an antenatal risk factor for referral to a CHW in the text. While mental health issues can certainly impact pregnancy and should be addressed, they may not always be included in the initial list of risk factors for referral to a CHW.

Therefore, the correct answer is: Having a previous history of depression or anxiety.

Congenital Cytomegalovirus (CMV) infection is a common viral infection that can be passed from mother to baby during pregnancy. It is estimated that CMV affects about 1 in 150 pregnancies. Of those pregnancies affected by CMV, about 30% will transmit the virus to the fetus. And of those fetuses that are infected with CMV, about 30% will show symptoms of the infection.

Therefore, out of 200 pregnancies, 1 will be affected by CMV. Out of those affected pregnancies, 30% will transmit the virus to the fetus, resulting in about 0.3 fetuses being infected. And out of those infected fetuses, about 30% will show symptoms of the infection, resulting in about 0.09 fetuses being affected.

So, the overall likelihood of a fetus being affected by congenital CMV infection is about 1 in 1500 pregnancies.

Endogenous transmission refers to the spread of infection by organisms that are normally present in the body but have become pathogenic due to certain conditions. This type of transmission occurs when the body’s own flora, which are usually harmless, gain access to a different part of the body where they can cause infection.

In contrast, exogenous transmission involves the introduction of pathogens from external sources. For example, inhalation of secretions containing a pathogen, direct person-to-person spread, transfer due to poor hygiene and contaminated food, and transfer from pets or other animals are all examples of exogenous infections.

Therefore, the statement Commensal flora that gain access to an inappropriate area best describes endogenous transmission, as it involves the activation of normally harmless flora within the body.

Isoniazid is the drug associated with peripheral neuropathy in this case. This side effect occurs due to a deficiency of biologically active pyridoxine (Vitamin B6). Isoniazid can combine with pyridoxine in the body to form a hydrazone, which is then excreted in the urine, leading to a decrease in the levels of pyridoxine available for normal bodily functions.

To prevent or reduce the risk of peripheral neuropathy associated with isoniazid, pyridoxine supplementation is often recommended. Pyridoxine is essential for nerve function and can help counteract the deficiency caused by isoniazid. Therefore, patients taking isoniazid for the treatment of Pulmonary Tuberculosis may also be prescribed pyridoxine to prevent peripheral neuropathy.

During syphilis treatment, it is important to monitor the RPR titer to assess the effectiveness of the treatment. If the RPR titer increases by four times or more, it may indicate treatment failure, reinfection, or a false positive result.

The correct course of action would be to repeat the RPR test to confirm the result. If the repeat test shows a significant increase in the RPR titer, it may be necessary to reevaluate the treatment plan. This could involve adjusting the dosage of antibiotics, switching to a different antibiotic, or considering the possibility of reinfection.

It is important to consult with a healthcare provider to determine the best course of action in this situation. Simply discontinuing treatment or increasing the dose of penicillin without proper evaluation could lead to ineffective treatment or unnecessary side effects. Continuing treatment as planned may not be appropriate if there is evidence of treatment failure or reinfection.

efavirenz is known to cause central nervous system side effects, including dizziness and ataxia, in some patients. These side effects typically occur within the first few weeks of starting the medication and may improve over time as the body adjusts to the drug. It is important for healthcare providers to monitor patients closely for these side effects and to consider alternative medications if they persist or worsen.

Hepatitis B surface antigen (HBsAg) is a protein on the surface of the hepatitis B virus, that is the first serologic marker to appear in a new acute infection.It can be detected as early as 1 week and as late as 9 weeks. It can be detected in high levels in serum during acute or chronic hepatitis B virus infection. The presence of HBsAg indicates that the person is infectious. The body normally produces antibodies to HBsAg as part of the normal immune response to infection. HBsAg is the antigen used to make hepatitis B vaccine.
Hepatitis B surface antibody (anti-HBs) indicates recovery and immunity from the hepatitis B virus infection. Anti-HBs also develops in a person who has been successfully vaccinated against hepatitis B.
Total hepatitis B core antibody (anti-HBc): Appears at the onset of symptoms in acute hepatitis B and persists for life. The presence of anti-HBc indicates previous or ongoing infection with hepatitis B virus in an undefined time frame. It is not present following hepatitis B vaccination.
IgM antibody to hepatitis B core antigen (IgM anti-HBc) indicates recent infection with hepatitis B virus (<6 months). Its presence indicates acute infection.
The following table summarises the presence of hepatitis B markers according to each situation:
Susceptible to infection:
HBsAg = Negative
Anti-HBc = Negative
Anti-HBs = Negative

Immune due to natural infection:
HBsAg = Negative
Anti-HBc = Positive
Anti-HBs = Positive

Immune due to vaccination:
HBsAg = Negative
Anti-HBc = Negative
Anti-HBs = Positive

Acute infection:
HBsAg = Positive
Anti-HBc = Positive
Anti-HBs = Negative
IgM anti-HBc = Positive

Chronic infection:
HBsAg = Positive
Anti-HBc = Positive
Anti-HBs = Negative
IgM anti-HBc = Negative

This question is testing the candidate’s knowledge of the management of infants exposed to maternal HIV. In this scenario, the 6-month-old girl has tested positive for HIV, despite being clinically healthy and meeting normal developmental milestones.

The most appropriate next step in this situation is to start co-trimoxazole prophylaxis immediately. Co-trimoxazole is recommended for all infants exposed to maternal HIV, regardless of their CD4 levels, to prevent opportunistic infections. Antiretroviral therapy is also necessary for infants with confirmed HIV infection, but it can wait until further work-up is complete.

Therefore, the correct answer is: Start co-trimoxazole prophylaxis immediately and plan to start antiretrovirals once further work-up is complete. This approach ensures that the infant receives the necessary prophylaxis to prevent infections while allowing time for additional testing and evaluation before starting antiretroviral therapy.

The weight-related eligibility criteria for TDF (Tenofovir Disoproxil Fumarate) were decreased from 35 kg to 30 kg according to the 2023 guidelines. This change was made to make TDF more accessible to a wider group of patients initiating antiretroviral therapy (ART). By lowering the weight requirement, more individuals who may benefit from TDF treatment will now be eligible to receive it. This change reflects a commitment to improving access to essential medications for all individuals living with HIV/AIDS, regardless of their weight.

The 34-year-old man who is HIV positive has started treatment for Burkitt lymphoma with chemotherapy. After one day of starting treatment, he becomes confused and complains of muscle cramps in his legs. These symptoms are most likely due to tumour lysis syndrome (TLS), which is a potentially fatal condition that can occur as a complication during the treatment of high-grade lymphomas and leukaemias.

TLS occurs when there is a rapid breakdown of tumour cells, leading to the release of chemicals into the bloodstream. This can result in electrolyte imbalances such as hyperkalaemia and hyperphosphatemia, along with hyponatraemia. The symptoms of TLS can include confusion, muscle cramps, and other neurological symptoms.

In this case, the introduction of chemotherapy likely triggered the development of TLS in the patient. It is important to be aware of this condition and to take steps for its prophylactic management. One such measure is the administration of rasburicase prior to chemotherapy, which helps reduce the risk of TLS by metabolizing uric acid to a more soluble form for renal excretion.

Burkitt lymphoma is a high-grade B-cell neoplasm associated with the c-myc gene translocation, usually t(8;14). The Epstein-Barr virus (EBV) is also implicated in the development of Burkitt lymphoma. Treatment for Burkitt lymphoma involves chemotherapy, which can lead to a rapid response and potentially trigger TLS.

Clients diagnosed with DS-TB at a non-neurological site with a CD4 count of less than 50 cells/μL are considered to have advanced HIV disease. In these cases, it is recommended to initiate ART within 2 weeks of starting TB treatment to reduce the risk of mortality and improve outcomes.

Initiating ART early in these patients can help to improve immune function, reduce the risk of opportunistic infections, and decrease the likelihood of TB treatment failure. Delaying ART in these individuals can lead to increased morbidity and mortality due to the high risk of disease progression and complications associated with advanced HIV disease.

Therefore, the correct action to take for clients diagnosed with DS-TB at a non-neurological site with CD4 < 50 cells/μL is to initiate ART within 2 weeks of starting TB treatment. This approach is in line with current guidelines and best practices for the management of HIV/TB co-infection in individuals with advanced HIV disease.